摘要
目的对大剂量阿糖胞苷在急性髓性白血病治疗中的临床运用效果进行探讨。方法整群选取2013年3月—2014年3月该院所收治的62例急性髓性白血病患者作为观察对象,按随机数字表法均分成观察组与对照组,对照组给予常规治疗,在此基础之上,对观察组患者予以大剂量阿糖胞苷治疗,且对两组患者的临床治疗效果进行观察与对比。结果观察组患者1年、3年以及5年的存活率均高于对照组患者,即83.9%vs48.4%、61.3%vs19.4%、29.0%vs0.0%,差异有统计学意义(P<0.05);不良反应发生率相比,差异无统计学意义(P>0.05)。结论对急性髓性白血病患者采取大剂量阿糖胞苷强化治疗,疗效确切,值得在临床上推行及运用。
Objective To discuss the clinical application effect of large-dose cytarabine in treatment of acute myeloid leukemia.Methods 62 cases of patients with acute myeloid leukemia admitted and treated in our hospital from March 2013 to March 2014 were selected as the observation objects and randomly divided into two groups,the control group were given the conventional treatment,the observation group were treated with large-dose cytarabine on this basis,and the clinical treatment effects of the two groups were observed and compared.Results The 1-year,3-year and 5-year survival rates in the observation group were higher than those in the control group,（83.9% vs 48.4%）,（61.3% vs 19.4%）,（29.0% vs 0.0%）,and the differences were obvious with statistical significance（P〈0.05）,and the difference in the incidence rate of adverse reactions had no statistical significance（P〉0.05）.Conclusion The curative effect of large-dose cytarabine intensive treatment for patients with acute myeloid leukemia is definite,which is worth clinical promotion and application.
出处
《中外医疗》
2016年第15期1-3,共3页
China & Foreign Medical Treatment
